CDK inhibitors in clinical development for the treatment of cancer

Expert Opinion on Investigational Drugs

Volumn 12, Issue 6, 2003, Pages 955-970

  Fischer, Peter M ^a   Gianella Borradori, Athos ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

7 hydroxystaurosporine; Aminothiazole; Bisindolylmaleimide; BMS 387032; CDK inhibitor; Cell cycle; CYC202; E7070; Flavopiridol; Indisulam; Protein kinase; Ro 31 7453; Roscovitine; UCN 01

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CAMPTOTHECIN; CARBOPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FLAVOPIRIDOL; FLUOROURACIL; INDISULAM; IRINOTECAN; KW 2401; MITOXANTRONE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RO 31 7453; ROSCOVITINE; TAMOXIFEN; THYMIDYLATE SYNTHASE; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LEUKOPENIA; LUNG CANCER; LUNG DISEASE; NEUTROPENIA; NONHUMAN; PROTEIN FUNCTION; REVIEW; SKIN MANIFESTATION; STOMACH CANCER; STRUCTURE ANALYSIS; THROMBOSIS;

ANIMALS; CLINICAL TRIALS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMANS; NEOPLASMS;

EID: 0038685911     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.6.955     Document Type: Review

References (149)

1. MORGAN DO, FISHER RP, ESPINOZA FH et al.: Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases. Cancer J. Sci. Am. (1998) 4(Suppl. 1):S77-S83.
2. KNOCKAERT M, GREENGARD P, MEIJER L: Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. (2002) 23:417-425.
3. MALUMBRES M, BARBACID M: To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer (2001) 1:222-231.
4. SAUSVILLE EA: Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. (2002) 8:S32-S37.
5. FISCHER PM: Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr. Opin. Drug Disc. Dev. (2001) 4:623-634.
6. FISCHER PM, LANE DP: Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. (2000) 7:1213-1245.
7. HARDCASTLE IR, GOLDING BT, GRIFFIN RJ: Designing inhibitors of cyclin-dependent kinases. Ann. Rev. Pharmacol. Toxicol. (2002) 42:325-348.
8. WEBSTER KR, BATORSKY R, MULHERON JG et al.: Discovery of 2-amino-5-thioalkylaryl thiazoles as novel inhibitors of cyclin dependent kinase 2. Proc. AACR-NCI-EORTC Intl. Conf.(2001) (Abstract 369).
9. TOOGOOD PL: Progress toward the development of agents to modulate the cell cycle. Curr. Opin. Chem. Biol. (2002) 6:472-478.
10. SEDLACEK HH, CZECH J, NAIK R et al.: Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. (1996) 9:1143-1168.
11. OMURA S, IWAI Y, HIRANO A et al.: A new alkaloid, AM-2282 of Streptomyces origin taxonomy, fermentation, isolation and preliminary characterization. J. Antibiot. (1977) 30:275-282.
12. TAKAHASHI I, SAITOH Y, YOSHIDA M et al.: UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J. Antibiot. (1989) 42:571-576.
13. KAWAKAMI K, FUTAMI H, TAKAHARA J et al.: UCN-01, 7-Hydroxyl-staurosporin, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res. Commun. (1996) 219:778-783.
14. GRAVES PR, YU L, SCHWARZ JK et al.: The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol Chem. (2000) 275:5600-5605.
15. HAVLICEK L, HANUS J, VESELY J et al.: Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. (1997) 40:408-412.
16. KIM KS, KIMBALL SD, MISRA RN et al.: Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities. J. Med. Chem. (2002) 45:3905-3927.
17. SEDLACEK HH: Mechanism of action of flavopiridol. Crit. Rev. Oncol. Hematol. (2001) 38:139-170.
18. SENDEROWICZ AM: Cyclin-dependent kinase modulators: A novel class of cell cycle regulators for cancer therapy. Cancer Chemother. Biol. Resp. Mod. (2001) 19:165-188.
19. SENDEROWICZ AM: Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia (2001) 15:1-9.
20. ZHAI S, SENDEROWICZ A, SAUSVILLE EA et al.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother. (2002) 36:905-911.
21. GROSIOS K: UCN-01 Kyowa Hakko Kogyo Co. Curr. Opin. Invest. Drugs (2001) 2:287-297.
22. SENDEROWICZ AM: The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist (2002) 7:12-19.
23. VAN KESTEREN C, BEIJNEN JH, SCHELLENS JHM: E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anticancer Drugs (2002) 13:989-997.
24. SUPURAN CT: Indisulam: an anticancer sulfonamide in clinical development. Expert Opin. Investig. Drugs (2003) 12:283-287.
25. DHINGRA U, KEN R, FISHTEYN D et al.: Characterization of and in vitro antiproliferative activity of Ro 31-7453, a new cell-cycle inhibitor. Proc. Am. Assoc. Cancer Res. (2000) 41 (Abstract 198).
26. AAMDAL S, SMYTH J, AWADA A et al.: Phase II study of e7070 in patients with metastatic melanoma (stage IV). Eur. J. Cancer (2002) 38(Suppl. 7):50.
27. OZAWA Y, KAI J, KUSANO K et al.: Combination of novel sulfonamide anticancer drug, E7070, with CPT-1: antitumor effect and synergistic mechanism. Eur. J. Cancer (2002) 38(Suppl. 7):17.
28. CASSIDY J, TWELVES C, BISSETT D et al.: Phase I clinical and pharmacokinetic study of the novel cell cycle inhibitor Ro 31-7453. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 731).
29. PAPADIMITRAKOPOULOU V, KIES M, GLISSON B et al.: A Phase I study of Ro 31-7453, a novel oral cell cycle inhibitor, in combination with paclitaxel: final results. Eur. J. Cancer (2002) 38(Suppl. 7):49.
30. PAULL KD, HAMEL E, MALSPEIS L: Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In: Cancer Chemotherapeutic Agents. WO Foye (Ed.), American Chemical Society (1995):9-45.
31. VAN DEN HEUVEL S, HARLOW E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science (1993) 262:2050-2054.
32. MCCLUE SJ, BLAKE D, CLARKE R et al.: In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer (2002) 102:463-468.
33. ALESSI F, QUARTA S, SAVIO M et al.: The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Exp. Cell Res. (1998) 245:8-18.
34. WHITTAKER S, WALTON M, GARRETT M et al.: Induction of the mitogen-activated protein kinase pathway by CYC202 (R-roscovitine). Proc. Am. Assoc. Cancer Res. (2002) 43(Abstract 3302).
35. WHITTAKER SR, POELE RT, WALTON MI et al: Gene expression profiling of the cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine). Eur. J. Cancer (2002) 38(Suppl. 7):50.
36. SEYNAEVE CM, KAZANIETZ MG, BLUMBERG PM et al.: Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol. Pharmacol. (1994) 45:1207-1214.
37. WANG Q, WORLAND PJ, CLARK JL et al.: Apoptosis in 7-hydroxystaurosporin-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ. (1995) 6:927-936.
38. AKINAGA S, SUGIYAMA K, AKIYAMA T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? Anticancer Drug Design (2000) 15:43-52.
39. SATO S, FUJITA N, TSURUO T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene (2002) 21:1727-1738.
40. KAUR G, STETLER-STEVENSON M, SEBERS S et al.: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. (1992) 84:1736-1740.
41. LI Y, CHINNI SR, SENDEROWICZ AM et al.: Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int. J. Oncol. (2000) 17:755-759.
42. MELILLO G, SAUSVILLE EA, CLOUD K et al.: Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. (1999) 59:5433-5437.
43. CZECH J, HOFFMANN D, NAIK R et al.: Antitumoral activity of flavone L 86-8275. Int. J. Oncol. (1995) 6:31-36.
44. BRUSSELBACH S, NETTELBECK DM, SEDLACEK H-H et al.: Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int. J. Cancer (1998) 77:146-152.
45. BIBLE KC, BIBLE RH, KOTTKE TJ et al.: Flavopiridol binds to duplex DNA. Cancer Res. (2000) 60:2419-2428.
46. CHAO S-H, FUJINAGA K, MARION JE et al.: Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. (2000) 275:28345-28348.
47. CHAO S-H, PRICE DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. (2001) 276:31793-31799.
48. ZAHAREVITZ DW, GUSSIO R, LEOST M et al.: Discovery and initial characetization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. (1999) 59:2566-2569.
49. FEAVER WJ, SVEJSTRUP JQ, HENRY NL et al.: Relationship of CDK-activating kinase and RNA polymerase II CTD kinase TFIIH/TFIIK. Cell (1994) 79:1103-1109.
50. NAPOLITANO G, MAJELLO B, LANIA L: Role of cyclinT/Cdk9 complex in basal and regulated transcription (Review). Int. J. Oncol, (2002) 21:171-177.
51. DENG L, AMMOSOVA T, PUMFERY A et al.: HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J. Biol. Chem. (2002) 277:33922-33929.
52. RICKERT P, CORDEN JL, LEES E: Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene (1999) 18:1093-1102.
53. LAM LT, PICKERAL OK, PENG AC et al.: Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. (2001) 2(10): Research 0041.
54. WANG Q, FAN S, EASTMAN A et al.: UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. (1996) 88:956-965.
55. MGBONYEBI OP, RUSSO J, RUSSO IH: Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res. (1999) 59:1903-1910.
56. LEE HR, CHANG TH, TEBALT MJ et al.: Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. Int. J. Oncol. (1999) 15:161-166.
57. ISEKI H, KO TC, XUE XY et al.: Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Surgery (1997) 122:187-194.
58. MIHARA M, SHINTANI S, KIYOTA A et al.: Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells. Int. J. Oncol. (2002) 21:95-101.
59. SOMERVILLE L, CORY JG: Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells. Anticancer Res. (2000) 20:3347-3355.
60. INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene (1998) 16:3087-3095.
61. SMITH V, RAYNAUD F, WORKMAN P et al.: Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Mol. Pharmacol. (2001) 60:885-893.
62. ROBEY RW, MEDINA-PEREZ WY, NISHIYAMA K et al.: Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res. (2001) 7:145-152.
63. BIBLE KC, BOERNER SA, KIRKLAND K et al.: Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin. Cancer Res. (2000) 6:661-670.
64. COURAGE C, SNOWDEN R, GESCHER A: Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells. Br. J. Cancer (1996) 74:1199-1205.
65. PATEL V, SENDEROWICZ AM, PINTO D et al.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest. (1998) 102:1674-1681.
66. ARGUELLO F, ALEXANDER M, STERRY JA et al.: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood (1998) 91:2482-2490.
67. RAYNAUD FI, NUTLEY BP, GODDARD PM et al.: Antitumour activity and oral bioavailability of the cyclin dependent kinase (CDK) inhibitor roscovitine. Proc. NCI-EORTC-AACR Symp. (2000) (Abstract 317).
68. SENDEROWICZ AM, SAUSVILLE EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (2000) 92:376-387.
69. KURATA N, KUWABARA T, TANII H et al.: Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Cancer Chemother. Pharmacol. (1999) 44:12-18.
70. - mice after iv administration. Proc. AACR-NCI-E0RTC Intl. Conf. (1999) (Abstract 541).
71. - mice. Proc. NCI-EORTC-AACR Symp. (2000) (Abstract 318).
72. JAGER W, ZEMBSCH B, WOLSCHANN P et al.: Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci. (1998) 62:1861-1873.
73. ALZANI R, TORRE PD, ALBANESE C et al: Ex vivo analysis to study the mode of action of a CDK2 inhibitor. Proc. Am. Assoc. Cancer Res. (2002) 43(Abstract 329).
74. HARRINGTON L, GRIFFIN R, EBERWEIN D et al.: Development of a retinoblastoma (RB) protein phosphorylation pharmacodynamic assay to measure CDK4 Ser/Thr kinase inhibition in human tumors. Proc. Am. Assoc. Cancer Res. (2002) 43(Abstract 4851).
75. STADLER WM, VOGELZANG NJ, AMATO R et al.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol. (2000) 18:371-375.
76. CHUNG Y-L, TROY H, JUDSON IR et al.: The effects of CYC202 on tumors monitored by magnetic resonance spectroscopy. Proc. Am. Assoc. Cancer Res. (2002) 43(Abstract 1664).
77. REDDY A, KAELIN WG Jr: Using cancer genetics to guide the selection of anticancer drug targets. Curr. Opin. Pharmacol. (2002) 2:366-373.
78. ELBASHIR SM, HARBORTH J, LENDECKEL W et al.: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494-498.
79. COLEY HM, SHOTTON CS, THOMAS H: The cyclin-dependent kinase inhibitor CYC202 is effective in human leiomyosarcoma (LMS) cell lines in combination with doxorubicin. Eur. J. Cancer (2002) 38(Suppl. 7):111.
80. LI W, FAN J, BERTTNO JR: Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cydin-dependent kinase 2 kinase activity. Cancer Res. (2001) 61:2579-2765.
81. COLEY H, SHOTTON C, THOMAS H: The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) is effective in human leiomyosarcoma (LMS) cell lines in combination with doxorubicin. Proc. Am. Assoc. Cancer Res. (2002) 43(Abstract 328).
82. ONGKEKO W, FERGUSON DJ, HARRIS AL et al.: Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J. Cell Sci. (1995) 108:2897-2904.
83. CHEN Y-NP, SHARMA SK, RAMSEY TM et al.: Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA (1999) 96:4325-4329.
84. DAVID-PFEUTY T: Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene (1999) 18:7409-7422.
85. LU W, CHEN L, PENG Y et al.: Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene (2001) 20:3206-3216.
86. ZHANG T, PRIVES C: Cyclin A-CDK phosphorylation regulates MDM2 protein interactions. J. Biol. Chem. (2001) 276:29702-29710.
87. BISCHOFF JR, FRIEDMAN PN, MARSHAK DR et al.: Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl. Acad. Sci. USA (1990) 87:4766-4770.
88. WANG Y, PRIVES C: Increased and altered DNA binding of human p53 by S and G2/ M but not G1 cyclin-dependent kinases. Nature (1995) 376:88-91.
89. BLAYDES JP, LUCLANI MG, POSPISILOVA S et al.: Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. J. Biol. Chem. (2001) 276:4699-4708.
90. BLAYDES JP, CRAIG AL, WALLACE M et al.: Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene (2000) 19:3829-3839.
91. GIACCIA AJ, KASTAN MB: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. (1998) 12:2973-2983.
92. LJUNGMAN M, PAULSEN MT: The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol. (2001) 60:785-789.
93. KOTALA V, ULDRIJAN S, HORKY M et al.: Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases. Cell. Mol. Life Sci. (2001) 58:1333-1339.
94. KORTMANSKY JS, MOTWANI MV, JUNG CP et al.: Flavopiridol potentiates the effect of radiotherapy in HCT-116 colon cancer xenografts. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 347).
95. MENG RD, SHIH H, PRABHU NS et al.: Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin. Cancer Res. (1998) 4:251-259.
96. JOHNSTON SR. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol. (2001) 2:18-26.
97. EDAMATSU H, GAU CL, NEMOTO T et al.: Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene (2000) 19:3059-3068.
98. KNUDSEN KE, WEBER E, ARDEN KC et al.: The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death. Oncogene (1999) 18:5239-5245.
99. SEPP-LORENZINO L, MA Z, RANDS E et al.: A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. (1995) 55:5302-5309.
100. WOLF D, ROTTER V: Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad Sci. USA (1985) 82:790-794.
101. MCKENNA WG, MUSCHEL RUTH J, GUPTA ANJALI K et al.: Farnesyltransferase inhibitors as radiation sensitizers. Semin. Rad. Oncol. (2002) 12:27-32.
102. KARP JE, KAUFMANN SH, ADJEI AA et al.: Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol. (2001) 13:470-476.
103. HOOIJBERG JH, BROXTERMAN HJ, HEIJN M et al.: Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett. (1997) 413:344-348.
104. HOOIJBERG JH, BROXTERMAN HJ, SCHEFFER GL et al.: Potent interaction of flavopiridol. with MRP1. Br. J. Cancer (1999) 81:269-276.
105. MONKS A, HARRIS ED, VAIGRO-WOLFF A et al.: UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Investig. New Drugs (2000) 18:95-107.
106. JACKSON JR, GILMARTTN A, IMBURGIA C et al.: An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. (2000) 60:566-572.
107. SCHWARTZ GK, ILSON D, SALTZ L et al.: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol. (2001) 19:1985-1992.
108. SHAPIRO GI, SUPKO JG, PATTERSON A et al.: A Phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin. Cancer Res. (2001) 7:1590-1599.
109. SCHNIER JB, KAUR G, KAISER A et al.: Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein. FEBS Lett. (1999) 454:100-104.
110. INNOCENTI F, STADLER WM, IYER L et al.: Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin. Cancer Res. (2000) 6:3400-3405.
111. BENNETT P, MANI S, O'REILLY S et al.: Phase II trial of flavopiridol in metastatic colorectal cancer: preliminary results (Meeting abstract). Proc. Am. Soc. Clin. Oncol. (1999) (Abstract).
112. TAN AR, HEADLEE D, MESSMANN R et al.: Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J. Clin. Oncol. (2002) 20:4074-4082.
113. BURDETTE-RADOUX S, TOZER RG, LOHMANN R et al.: NCIC CTG Phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma (IND.137). Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 1382).
114. MURTHY A, KARP J, BAUER K et al.: Correlative studies of acute leukemia patients treated with flavopiridol: endothelial cell (EC) proliferation as a marker of anti-angiogenesis. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 1089).
115. SASAKI Y, SASAKI T, MINAMI H et al.: A Phase I pharmacokinetic (PK)-pharmacodynamic (PD) study of flavopiridol by 24 hours continuous infusion (CI) repeating every week. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 371).
116. SCHWARTZ GK, O'REILLY E, ILSON D et al.: Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol. (2002) 20:2157-2170.
117. GRIES J, KASIMIS B, SCHWARZENBERGER P et al.: Phase I study of flavopiridol (HMR1275) in combination with paclitaxel and carboplatin in non-small cell lung cancer (NCSLC) patients. Eur. J. Cancer (2002) 38(Suppl. 7):49.
118. MOTWANI M, JUNG C, SIROTNAK FM et al.: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin. Cancer Res. (2001) 7:4209-4219.
119. SHAH MA, KORTMANSKY J, GONEN M et al.: A Phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopiridol (F). Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 373).
120. TAN AR, ZHAI S, BERMAN AW et al.: Phase I trial of docetaxel followed by infusional flavopiridol over 72 hours in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 1955).
121. BIBLE KC, LENSING JL, NELSON SA et al.: A Phase I trial of flavopiridol combined with cisplatin in patients with advanced malignancies. Proc. Am. Assoc. Cancer Res. (2002) 43(Abstract 2749).
122. SAUSVILLE EA, ARBUCK SG, MESSMANN R et al.: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. (2001) 19:2319-2333.
123. FUSE E, TANII H, KURATA N et al.: Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. (1998) 58:3248-3253.
124. FUSE E, TANII H, TAKAI K et al.: Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha 1-acid glycoprotein in humans. Cancer Res. (1999) 59:1054-1060.
125. DEES E, O'REILLY S, FIGG W et al.: A Phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 797).
126. TAMURA T, SASAKI Y, MINAMI H et al.: Phase I study of UCN-01 by 3-hour infusion. Proc. Am. Soc. Clin. Oncol. (1999) (Abstract).
127. KOH J-I, KUBOTA T, KOYAMA T et al.: Combined antitumor effect of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma cell. Proc. Am. Assoc. Cancer Res. (2002) 43(Abstract 4855).
128. HSUEH C-T, KELSEN D, SCHWARTZ GK: UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin. Cancer Res. (1998) 4:2201-2206.
129. BENSON C, RAYNAUD F, O'DONNELL A et al.: Pharmacokinetics (PK) of the oral cyclin dependent kinase inhibitor CYC202 (R-roscovidne) in patients with cancer. Proc. Am. Assoc. Cancer Res. (2002) 43:1354.
130. COHEN P: Protein kinases - the major drug targets of the twenty-first century?. Nat. Rev. Drug Disc. (2002) 1:309-315.
131. FISCHER PM, ENDICOTT J, MEIJER L: Cyclin-dependent kinase inhibitors. In: Progress in Cell Cycle Research (Vol. 5). L Meijer, A Jézéquel, M Roberge (Eds), Editions de la Station Biologique de Roscoff (2003):235-248.
132. FUKUOKA K, USUDA J, IWAMOTO Y et al.: Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Investig. New Drugs (2001) 19:219-227.
133. RONINSON IB, BROUDE EV, CHANG BD: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. (2001) 4:303-313.
134. WALKER DH, MALLER JL: Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature (1991) 354:314-317.
135. MIHAYLOV IS, KONDO T, JONES L et al.: Control of DNA replication and chromosome ploidy by geminin and cyclin A. Mol. Cell. Biol. (2002) 22:1868-1880.
136. PAGANO M, PEPPERKOK R, VERDE F et al.: Cyclin A is required at two points in the human cell cycle. EMBO J. (1992) 11:961-971.
137. JACKMAN M, KUBOTA Y, DEN ELZEN N et al.: Cyclin A- and cyclin E-Cdk complexes shuttle between the nucleus and the cytoplasm. Mol. Biol. Cell (2002) 13:1030-1045.
138. FURUNO, N, ELZEN ND, PINES J: Human cyclin A is required for mitosis until mid prophase. J. Cell Biol. (1999) 147:295-306.
139. FAIVRE J, FRANK-VAILLANT M, POULHE R et al.: Centrosome overduplication, increased ploidy and transformation in cells expressing endoplasmic reticulum-associated cyclin A2. Oncogene (2002) 21:1493-1500.
140. HRICIK DE, CHUNG-PARK M, SEDOR JR: Glomenrulonephritis. N. Engl. J. Med. (1998) 339:888-899.
141. PIPPIN JW, QU Q, MEIJER L et al.: Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist. J. Clin. Invest.(1997) 100:2512-2520.
142. HIROMURA. K, PIPPIN JW, BLONSKI MJ et al.: The subcellular localization of cyclin dependent kinase 2 determines the fate of mesangial cells: role in apoptosis and proliferation. Oncogene (2002) 21:1750-1758.
143. CLOUGH J: CDK inhibitor shows promise for inflammatory kidney disease. Drug Disc. Today (2002) 7:789-790.
144. SCHANG LM: Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. (2002) 50:779-792.
145. NELSON PJ, GELMAN IH, KLOTMAN PE: Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. J. Am. Soc. Nephrol. (2001) 12:2827-2831.
146. WANG D, DE LA FUENTE C, DENG L et al.: Inhibition of human immunodeficiency virus Type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. (2001) 75:7266-7279.
147. SCHANG LM, ROSENBERG A, SCHAFFER PA: Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J. Virol. (1999) 73:2161-2172.
148. ZHAO B, BOWER MJ, MCDEVITT PJ et al.: Structural Basis for Chk1 inhibition by UCN-01. J. Biol. Chem. (2002) 277:46609-46615.
149. WANG S, MCCLUE SJ, FERGUSON JR et al.: Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry (2001) 12:2891-2894.